Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rosa Maria Di Mauro"'
Autor:
Claudia Proto, Sara Manglaviti, Giuseppe Lo Russo, Marco Musca, Giulia Galli, Martina Imbimbo, Matteo Perrino, Nadia Cordua, Eliana Rulli, Zelmira Ballatore, Alessandro Dal Maso, Antonio Chella, Andrea Sbrana, Arsela Prelaj, Roberto Ferrara, Mario Occhipinti, Marta Brambilla, Alessandro De Toma, Laura Mazzeo, Teresa Beninato, Diego Signorelli, Giacomo Massa, Francesca Gabriella Greco, Giuseppina Calareso, Daniela Miliziano, Rosa Maria Di Mauro, Giulia Mella, Alessandra Lucarelli, Angela Paggio, Francesca Galli, Valter Torri, Filippo Guglielmo Maria de Braud, Giulia Pasello, Iacopo Petrini, Rossana Berardi, Monica Ganzinelli, Marina Chiara Garassino, Paolo Andrea Zucali
Publikováno v:
Journal of Thoracic Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2375ed575ffb6584f90354f4af231b2
https://doi.org/10.1016/j.jtho.2023.04.009
https://doi.org/10.1016/j.jtho.2023.04.009
Autor:
Emma Zattarin, Giuseppe Viscardi, Elisa Sottotetti, A. Prelaj, Marta Brambilla, Giulia Galli, Riccardo Lobefaro, Monica Ganzinelli, Claudia Proto, Roberto Ferrara, Rosa Maria Di Mauro, Sara Manglaviti, Diego Signorelli, Marta Bini, Mario Occhipinti, Giuseppe Lo Russo, Giulia Apollonio, Giacomo Massa, Teresa Beninato, Filippo de Braud, Alessandra Fabbri, A. Bottiglieri, M.C. Garassino, Alessandro De Toma, Benedetta Trevisan
Immune-checkpoint inhibitors (ICIs) have significantly improved outcome of advanced non-small cell lung cancer (aNSCLC) patients. However, their efficacy remains uncertain in uncommon histologies (UH).Data from ICI treated aNSCLC patients (April,2013
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b70881691456c954295bf0bd93b2c0b
http://hdl.handle.net/11311/1220885
http://hdl.handle.net/11311/1220885
Autor:
Giuseppe Lo Russo, Monica Ganzinelli, Francesco Sgambelluri, Francesca Galli, Arsela Prelaj, Sara Manglaviti, Achille Bottiglieri, Rosa Maria Di Mauro, Roberto Ferrara, Andra Diana Dumitrascu, Elisa Sottotetti, Antonia Martinetti, Alessandra Fabbri, Eliana Rulli, Filippo G. De Braud, Valter Torri, Marina Chiara Garassino, Andrea Anichini, Claudia Proto, Roberta Mortarini
Publikováno v:
Journal of Clinical Oncology. 40:9033-9033
9033 Background: In advanced NSCLC (aNSCLC) with PD-L1 < 50% chemo-immunotherapy is the standard of care. Although the activity of single agent pembrolizumab was reported, no biomarkers have been identified able to select patients who mostly benefit.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebc7c26a03b979ba2d046c429c87cd77
https://doi.org/10.1200/jco.2022.40.16_suppl.9033
https://doi.org/10.1200/jco.2022.40.16_suppl.9033
Autor:
Benedetta Trevisan, Diego Signorelli, Marta Brambilla, Arsela Prelaj, Rosa Maria Di Mauro, Giulia Galli, Rosaria Gallucci, Giuseppe Viscardi, Sara Elena Rebuzzi, Claudia Proto, Valter Torri, Filippo Pagani, Antonia Martinetti, Giuliano Molino, Alessandro De Toma, Marina Chiara Garassino, Giuseppe Lo Russo, Roberto Ferrara, Nicoletta Zilembo, Filippo Maria de Braud, Giovanni Randon, Monica Ganzinelli
Publikováno v:
Cancers
Volume 11
Issue 12
Volume 11
Issue 12
Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative Oncology Group performance status (ECOG PS), smoking, liver metastases, lactate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd24b173dfd8e3b815180ef54aee7d54
http://hdl.handle.net/11311/1145194
http://hdl.handle.net/11311/1145194